| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |